ReviewFrontiers in molecular biosciences2023
Pathological identification of HER2-low breast cancer: Tips, tricks, and troubleshooting for the optimal test.
Review in Frontiers in molecular biosciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 38 citations in OpenAlex.
- Redefining breast cancer: therapeutic opportunities in HER2-low and emerging molecular subtypes.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Trastuzumab Deruxtecan for HER2-Low Metastatic Breast Cancer: Practical Considerations for Medical Oncologists and Pathologists in Australia.Asia-Pacific journal of clinical oncology · 2026Review
- Addressing the Challenges in the Identification of HER2-Low and Ultralow Breast Cancer in Asia: A Delphi Consensus.Advances in therapy · 2026Article
- High accuracy in detecting HER2-low status in FNA of primary and metastatic breast cancer.Cancer cytopathology · 2026Article
- Impact of Ethnic Differences and HER2 Protein Expression on the Age at Breast Cancer Diagnosis: A Mixed Methods Study.Cancer management and research · 2026Article
- HER2 expression in breast cancer: evidence gaps and challenges.NPJ precision oncology · 2025Review
- HER2-Low and HER2-Ultralow Metastatic Breast Cancer and Trastuzumab Deruxtecan: Common Clinical Questions and Answers.Cancers · 2025Review
- HER2-low breast cancer is immune-cold: insights into tumor-infiltrating immune cells and implications for immunotherapy.NPJ breast cancer · 2025Article
- Challenges & recommendations for identification of human epidermal growth factor receptor -2 (HER2)-low metastatic breast cancer in India: Expert opinion statement.The Indian journal of medical research · 2025Review
- Real-world treatment patterns and outcomes of patients with hormone receptor-positive/HER2-low metastatic breast cancer treated with chemotherapy.The oncologist · 2025Article
- HER2-Low Breast Cancer-Current Knowledge and Future Directions.Medicina (Kaunas, Lithuania) · 2025Review
- Computational pathology in the identification of HER2-low breast cancer: Opportunities and challenges.Journal of pathology informatics · 2024Review
- Breast cancer in northern Peru: molecular subtypes and HER2 low.Revista peruana de medicina experimental y salud publica · 2024Article
- Early Breast Cancer Risk Assessment: Integrating Histopathology with Artificial Intelligence.Cancers · 2024Review
- Novel approach to HER2 quantification using phosphor-integrated dots in human breast invasive cancer microarray.PloS one · 2024Article
- Study design for DESTINY-Breast Respond HER2-low Europe: T-DXd in patients with HER2-low advanced breast cancer.Future oncology (London, England) · 2024Observational
- Standardized pathology report for HER2 testing in compliance with 2023 ASCO/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer.Virchows Archiv : an international journal of pathology · 2024Review
- Think "HER2" different: integrative diagnostic approaches for HER2-low breast cancer.Pathologica · 2023Review
- Integrated Molecular Characterization of HER2-Low Breast Cancer Using Next Generation Sequencing (NGS).Biomedicines · 2023Article
- Molecular and serological biomarkers to predict trastuzumab responsiveness in HER-2 positive breast cancer.Journal of medicine and life · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The introduction of novel anti-HER2 antibody-drug conjugates (ADC) for the treatment of HER2-low breast cancers has transformed the traditional dichotomy of HER2 status to an expanded spectrum. However, the identification of HER2-low (i.e., immunohistochemistry (IHC) score 1 + or IHC score 2+, without gene amplification) tumors is challenged by methodological and analytical variables that might influence the sensitivity and reproducibility of HER2 testing. To open all possible therapeutic opportunities for HER2-low breast cancer patients the implementation of more accurate and reproducible testing strategies is mandatory. Here, we provide an overview of the existing barriers that may trouble HER2-low identification in breast cancer and discuss practical solutions that could enhance HER-low assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.